ATR logo

APTARGROUP INC

ATRNYSE
πŸ† #1011 by market capEarnings Oct 29US Equity
$123.29β–Ό $1.15 (βˆ’0.93%)
Market closed Β· at close
πŸ””
Track ATR
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 0.9%
7dβ–Ό 1.3%
14dβ–Ό 1.2%
30dβ–Ό 6.3%
ytdβ–² 1.1%
1yβ–Ό 7.8%
🏦Market Cap
$7.87B
Small Cap
πŸ“ˆRevenue Growth (YoY)
+5.4%
Slowing
πŸ“ŠGross Margin
28.3%
Moderate
πŸ’΅FCF Margin
7.9%
Moderate
βš–οΈP/S Ratio
2.0x
Cheap
Otter Score
84
Good

Trading Snapshot

Day Range
$122.77 – $125.57
52-Week Range
$103.23 – $146.91
Volume
$4.16B
Avg Volume
$4.04B
Shares Outstanding
63.8M
Next Earnings
Oct 25, 2026

Fundamentals Snapshot

Annual Revenue
$3.78B
Last Q Revenue
$1.03B
P/E Ratio
22.0
P/S Ratio
2.0x
EPS (TTM)
$5.68
Dividend Yield
1.56%
Dilution (1yr)
βˆ’3.1%

Why Investors Own ATR

  • βœ“High-growth profile β€” revenue up +44.0% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 74% gross margin and 14% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

ATR logo

APTARGROUP INC

ATR
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$3.8Bβ–² +5.4% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
29.6%β–Ό βˆ’21.8% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$512Mβ–² +3.2% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$300Mβ–Ό βˆ’14.2% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
65.8Mβ–Ό βˆ’3.1% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$1.1Bβ–Ό βˆ’$276M YoY
StockOtter Β· stockotter.space

About APTARGROUP INC

AptarGroup, Inc. specializes in developing and manufacturing solutions for dispensing, sealing, and advanced material science, catering to a broad spectrum of industries such as beauty, personal care, home care, and the pharmaceutical sector (including prescription drugs, consumer health care, and injectables), alongside the food and beverage markets. Its operations are structured into three key segments: Pharma, Beauty + Home, and Food + Beverage. The Pharma division offers critical components for the pharmaceutical industry, including pumps for nasal allergy remedies, metered dose inhaler valves vital for managing respiratory conditions like asthma and chronic obstructive pulmonary disease (COPD), elastomeric primary packaging for injectables, and sophisticated active material science innovations. The Beauty + Home segment primarily supplies the personal care and home care sectors with essential products such as pumps, various closures, aerosol valves, accompanying accessories, and sealing mechanisms. It also furnishes the beauty market with pumps and decorative elements. For the food and beverage industries, its Food + Beverage segment delivers a variety of dispensing and non-dispensing closures, specialized elastomeric flow control components, spray pumps, and aerosol valves. AptarGroup markets its offerings globally, utilizing its internal sales team, complemented by independent representatives and distributors across Asia, Europe, Latin America, and North America. The company is engaged in a strategic partnership with PureCycle Technologies LLC to pioneer the integration of ultra-pure recycled polypropylene into advanced dispensing applications. Additionally, it collaborates with Sonmol on the development of a digital platform providing therapies and services, with a particular focus on respiratory and other health conditions. Established in 1992, AptarGroup, Inc. maintains its corporate headquarters in Crystal Lake, Illinois.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Good
84/100

Analyst Price Target

β“˜
Average Target
$152.75
β–² +23.9% Upside
High Target$169.26
Low Target$134.20
Based on 22 analysts

Latest News & Updates

Zacks Investment ResearchΒ·4d ago

3 Packaging Stocks Worth Watching Despite Industry Pressure

Although weak demand and tariffs cloud the Zacks Containers - Paper and Packaging industry's near-term outlook, AVY, ATR and KRT are navigating the challenges well.

Defense WorldΒ·13d ago

AptarGroup, Inc. $ATR Shares Sold by Tidal Investments LLC

Tidal Investments LLC lowered its position in AptarGroup, Inc. (NYSE: ATR) by 24.4% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 17,987 s

Defense WorldΒ·14d ago

VIRGINIA RETIREMENT SYSTEMS ET Al Buys New Holdings in AptarGroup, Inc. $ATR

VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in AptarGroup, Inc. (NYSE: ATR) in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 4,200

Seeking AlphaΒ·14d ago

AptarGroup, Inc. (ATR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

AptarGroup, Inc. (ATR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking AlphaΒ·20d ago

AptarGroup, Inc. (ATR) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

AptarGroup, Inc. (ATR) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

PRNewsWireΒ·27d ago

CytoSorbents Announces New Real-World Data Demonstrating Significant Reduction in Severe Bleeding Using CytoSorb in CABG Patients on Ticagrelor and Updates Recent DrugSorb-ATR FDA Pre-Submission Meetings

Patient-level matched analysis of real-world data demonstrated a significant 37% relative reduction in severe bleeding Significant reductions in 24-hour chest tube drainage and red blood cell transfusions were also seen,